Treatment
onychomycosis treatment antifungal
Important: Before starting oral antifungals, laboratory confirmation is recommended. Approximately one-third of clinically suspected onychomycosis cases do not have fungal infection. A KOH preparation, fungal culture, or PCR test should confirm the organism. - Goodman & Gilman's Pharmacological Basis of Therapeutics
| Fingernails | Toenails | |
|---|---|---|
| Dose | 250 mg/day | 250 mg/day |
| Duration | 6 weeks | 12 weeks |
| Alternative pulsed dosing | 500 mg/day x 1 week/month x 3 months | same |
| Fingernails | Toenails | |
|---|---|---|
| Continuous dose | 200 mg/day x 6 weeks | 200 mg/day x 12 weeks |
| Pulsed dose | 400 mg/day x 1 week/month x 2 months | 400 mg/day x 1 week/month x 3 months |
Sources: Goldman-Cecil Medicine; Goodman & Gilman's Pharmacological Basis of Therapeutics; PMID 40827600 (2025 meta-analysis on 40% urea adjuvant therapy)
⚠️ Disclaimer: This is for educational purposes only. Please consult a healthcare provider for personal medical advice and before starting any prescription medication.
Treatment plan
onychomycosis treatment guidelines oral antifungal
| Action | Purpose |
|---|---|
| KOH preparation of nail scraping | Rapid in-clinic confirmation of fungal hyphae |
| Fungal culture (nail clippings/debris) | Identifies organism: dermatophyte vs. Candida vs. non-dermatophyte mold |
| Baseline LFTs (AST, ALT) | Mandatory before starting oral antifungals |
| Rule out psoriasis, trauma, lichen planus | Avoid treating non-fungal nail dystrophy with antifungals |
Approximately 1 in 3 clinically suspected cases are NOT fungal. Confirm before prescribing. - Goodman & Gilman's
| Parameter | Detail |
|---|---|
| Dose | 250 mg orally once daily |
| Duration (fingernail) | 6 weeks |
| Duration (toenail) | 12 weeks |
| Mechanism | Inhibits fungal squalene epoxidase → fungicidal |
| Organism coverage | Dermatophytes (T. rubrum, T. interdigitale) - first-line |
| NOT effective for | Candida or non-dermatophyte molds |
| Parameter | Detail |
|---|---|
| Dose | 200 mg/day continuously OR pulse: 400 mg/day x 1 week/month |
| Duration (fingernail) | 6 weeks continuous / 2 months pulsed |
| Duration (toenail) | 12 weeks continuous / 3 months pulsed |
| Drug interactions | Check for CYP3A4 interactions; avoid with certain statins, antacids |
| Agent | Application | Evidence |
|---|---|---|
| Ciclopirox 8% nail lacquer | Daily; remove weekly with alcohol | Adjunct to oral therapy |
| Efinaconazole 10% solution | Daily; do not wash off for 10 min | FDA-approved for mild-moderate toenail OM |
| 40% Urea cream | Apply to nail plate nightly, occlude with wrap | Softens/debrides nail, improves antifungal penetration (2025 meta-analysis, PMID 40827600) |
| Timepoint | Action |
|---|---|
| Week 4-6 | LFTs; assess symptoms; check for adverse effects |
| Week 8-12 | Clinical assessment - new healthy nail growth visible from proximal end? |
| Month 6 | Evaluate for mycological cure (KOH/culture) |
| Month 12 | Full nail regrowth expected (fingernail ~6 months; toenail ~12-18 months) |
| Measure | Rationale |
|---|---|
| Keep nails short and dry | Reduces fungal habitat |
| Change socks daily; breathable footwear | Prevents reinfection from tinea pedis |
| Treat tinea pedis concurrently if present | Major reservoir for nail reinfection |
| Antifungal foot powder in shoes | Suppressive |
| Avoid barefoot contact in gyms/pools/bathrooms | Environmental exposure |
| Monthly self-inspection | Early detection of relapse |
| Situation | Adjustment |
|---|---|
| Hepatic disease | Terbinafine and itraconazole both contraindicated - topical only |
| Renal impairment (moderate-severe) | Terbinafine dose reduction; itraconazole with caution |
| Elderly / polypharmacy | Screen for drug interactions (itraconazole is a strong CYP3A4 inhibitor) |
| Immunocompromised | More aggressive therapy; consider specialist referral |
| Nail matrix involvement | Longer treatment course; lower cure rates |
Day 0 → Confirm diagnosis (KOH + culture) + baseline LFTs
Day 1 → Start Terbinafine 250 mg/day + topical ciclopirox/urea + nail trimming
Week 6 → Stop terbinafine (fingernail) | LFTs recheck
Month 3 → Assess proximal nail regrowth; KOH to confirm clearance
Month 6 → Full clinical and mycological cure expected for fingernail
Month 12+ → Recurrence monitoring and prevention
Sources: Fitzpatrick's Dermatology; Goodman & Gilman's Pharmacological Basis of Therapeutics; Goldman-Cecil Medicine; Practice Guideline PMID 37212291 (S1 Guideline onychomycosis, 2023)
⚠️ This treatment plan is for clinical educational reference. Individual management should be guided by a licensed healthcare provider based on confirmed diagnosis, patient history, and local drug availability.